These results strongly suggest that the amount of EGFR sensitizing mutations in plasma reflects the tumor burden and that the fluctuations in the levels of EGFR sensitizing mutations in plasma are closely related to tumor load variations [4–8]. The gene discussed is EGFR; the disease is neoplasm.